Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.4%

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Free Report) was up 6.4% on Wednesday . The company traded as high as $14.00 and last traded at $13.62. Approximately 83,178 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 931,872 shares. The stock had previously closed at $12.80.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on STOK shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Canaccord Genuity Group reduced their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 6th. Wedbush upped their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Finally, TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $20.57.

Read Our Latest Stock Analysis on STOK

Stoke Therapeutics Stock Up 10.4 %

The business’s 50-day moving average price is $10.67 and its 200-day moving average price is $6.98. The firm has a market capitalization of $736.46 million, a PE ratio of -5.66 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analysts’ expectations of $3.70 million. On average, analysts anticipate that Stoke Therapeutics, Inc. will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 5,126 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $13.20, for a total value of $67,663.20. Following the transaction, the general counsel now owns 2,598 shares in the company, valued at approximately $34,293.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,622,741 shares of company stock worth $41,935,115. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dorsey & Whitney Trust CO LLC bought a new position in Stoke Therapeutics in the third quarter worth $43,000. Sherbrooke Park Advisers LLC bought a new position in shares of Stoke Therapeutics during the third quarter valued at $48,000. SG Americas Securities LLC bought a new position in shares of Stoke Therapeutics during the third quarter valued at $53,000. Corton Capital Inc. bought a new position in shares of Stoke Therapeutics during the third quarter valued at $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Stoke Therapeutics during the third quarter valued at $64,000.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Further Reading

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.